Dianthus Therapeutics, Inc. /DE/ (DNTH) /
The cash flow of Dianthus Therapeutics, Inc. /DE/ over the past 10 years
Chart Dianthus Therapeutics, Inc. /DE/: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Dianthus Therapeutics, Inc. /DE/'s operating cash flow was -$129.06M and its capital expenditures $213K, leaving free cash flow of -$129.27M. Free cash flow was below zero in all 10 years shown. It ranged from -$129.27M in fiscal 2025 to -$6.67M in fiscal 2016. Capital expenditures were highest in fiscal 2018, at $7.67M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$129.06M | $213K | -$129.27M |
| 2024ended Dec 31, 2024 | -$78.18M | $105K | -$78.28M |
| 2023ended Dec 31, 2023 | -$36.86M | $110K | -$36.97M |
| 2022ended Dec 31, 2022 | -$29.07M | $139K | -$29.21M |
| 2021ended Dec 31, 2021 | -$59.53M | $1.26M | -$60.8M |
| 2020ended Dec 31, 2020 | -$64.02M | $400K | -$64.42M |
| 2019ended Dec 31, 2019 | -$57.1M | $3.06M | -$60.16M |
| 2018ended Dec 31, 2018 | -$41.89M | $7.67M | -$49.56M |
| 2017ended Dec 31, 2017 | -$22.26M | $2.2M | -$24.46M |
| 2016ended Dec 31, 2016 | -$6.53M | $139K | -$6.67M |
Fiscal years as Dianthus Therapeutics, Inc. /DE/ reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Dianthus Therapeutics, Inc. /DE/
- The revenue of Dianthus Therapeutics, Inc. /DE/
- The profitability of Dianthus Therapeutics, Inc. /DE/
- The debt of Dianthus Therapeutics, Inc. /DE/
- All of Dianthus Therapeutics, Inc. /DE/'s financials, charted
Companies of a similar size
- EPREPR PROPERTIES
- PAYPaymentus Holdings, Inc.
- IESCIES Holdings, Inc.
- HRIHERC HOLDINGS INC.
- GNTXGENTEX CORPORATION
Not investment advice. This page shows what Dianthus Therapeutics, Inc. /DE/ filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.